Current and emerging treatments for amyotrophic lateral sclerosis

References

• RowlandLPShneiderNAAmyotrophic lateral sclerosisN Engl J Med20013441688170011386269
   PubMed Web of Science ®Google Scholar
• GoodallEFMorrisonKEAmyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatmentExpert Rev Mol Med2006812216723044
   PubMedGoogle Scholar
• RothsteinJDCurrent hypotheses for the underlying biology of amyotrophic lateral sclerosisAnn Neurol200965SupplS3S919191304
   PubMed Web of Science ®Google Scholar
• PioroEPMitsumotoHAnimal models of ALSClin Neurosci1995–1996363753859021259
   PubMedGoogle Scholar
• BruijnLIMillerTMClevelandDWUnraveling the mechanisms involved in motor neuron degeneration in ALSAnnu Rev Neurosci20042772374915217349
   PubMed Web of Science ®Google Scholar
• MillerRGMitchellJDLyonMMooreDHRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Cochrane Database Syst Rev20071CD00144717253460
   PubMed Web of Science ®Google Scholar
• MitchellJDBorasioGDAmyotrophic lateral sclerosisLancet20073692031204117574095
   PubMed Web of Science ®Google Scholar
• TraynorBJBruijnLConwitRNeuroprotective agents for clinical trials in ALS: a systematic assessmentNeurology200667202716832072
   PubMed Web of Science ®Google Scholar
• GurneyMEFleckTJHimesCSHallEDRiluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosisNeurology19985062669443458
   PubMed Web of Science ®Google Scholar
• TraynorBJAlexanderMCorrBFrostEHardimanOAn outcome study of riluzole in amyotrophic lateral sclerosis. A population based study in Ireland, 1996–2000J Neurol200325047347912700914
   PubMed Web of Science ®Google Scholar
• ZoccolellaSBeghiEPalaganoGRiluzole and amyotrophic lateral sclerosis survival: a population-based study in southern ItalyEur J Neurol20071426226817355545
   PubMed Web of Science ®Google Scholar
• DunlopJBeal McIlvainHYijinSHowlandDSImpaired spinal cord glutamate transport capacity and reduced sensitivity to Riluzole in a transgenic superoxidedismutase mutant rat model of amyotrophic lateral sclerosisJ Neurosci2003231688169612629173
   PubMed Web of Science ®Google Scholar
• ChenHSPellegriniJWAggarwalSKOpen-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicityJ Neurosci199212442744361432103
   PubMed Web of Science ®Google Scholar
• VolbrachtCvan BeekJZhuCBlomgrenKLeistMNeuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicityEur J Neurosci2006232611262216817864
   PubMed Web of Science ®Google Scholar
• ReisbergGDoodyRStofflerASchmittFFerrisSMobiusHJMemantine Study GroupMemantine in moderate-to-severe Alzheimer’s diseaseN Engl J Med20033481333134112672860
   PubMed Web of Science ®Google Scholar
• WangRZhangDMemantine prolongs survival in an amyotrophic lateral sclerosis mouse modelEur J Neurosci2005222376238016262676
   PubMed Web of Science ®Google Scholar
• JooISHwangDHSeokJIShinSKKimSUOral administration of memantine prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosisJ Clin Neurol2007318118619513129
   PubMed Web of Science ®Google Scholar
• ALS AssociationClinical trialsAvailable from: http://www.alsa.org/patient/drug.cfm Accessed on October 10, 2009.
   Google Scholar
• LeeJRyuHKowallNWMotor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS miceBiochem Biophys Res Commun200938452452919427829
   PubMed Web of Science ®Google Scholar
• IłzeckaJStelmasiakZSolskiJWawrzyckiSSzpetnarMPlasma amino acids concentration in amyotrophic lateral sclerosis patientsAmino Acids2003251697312836061
   PubMed Web of Science ®Google Scholar
• RothsteinJDPatelSReganMRBeta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expressionNature2005433737715635412
   PubMed Web of Science ®Google Scholar
• JiHFShenLZhangHYBeta-lactam antibiotics are multipotent agents to combat neurological diseasesBiochem Biophys Res Commun200533366166315907788
   PubMed Web of Science ®Google Scholar
• BedlackRSTraynorBJCudkowiczMEEmerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosisExpert Opin Emerg Drugs20071222925217604499
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Clinical trial ceftriaxone in subjects with ALS. July 21, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00349622 Accessed on October 10, 2009.
   Google Scholar
• AkaikeATamuraYSatoYYokotaTProtective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neuronsEur J Pharmacol1993241167901032
   PubMed Web of Science ®Google Scholar
• ZhangXChenSLiLWangQLeWFolic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1(G93A) transgenic miceNeuropharmacology2008541112111918436268
   PubMed Web of Science ®Google Scholar
• LeeKWParkJHKimMYNeuroprotective effects of multi-vitamin therapy in a transgenic mouse model of amyotrophic lateral sclerosis [abstract]Amyotroph Lat Scler20067Suppl 1122123
   Google Scholar
• KajiRKodamaMImamuraAEffect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled studyMuscle Nerve199821177517789843082
   PubMed Web of Science ®Google Scholar
• IzumiYKajiRClinical trials of ultra-high-dose methylcobalamin in ALSBrain Nerve2007591141114717969354
   PubMedGoogle Scholar
• ThomasAGWozniakKMTsukamotoTGlutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategyAdv Exp Med Biol200657632733716802724
   PubMed Web of Science ®Google Scholar
• GhadgeGDSlusherBSBodnerAGlutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis modelsProc Natl Acad Sci U S A2003100169554995912876198
   PubMed Web of Science ®Google Scholar
• MaragakisNJJacksonMGanelRRothsteinJDTopiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic miceNeurosci Lett2003338210711012566164
   PubMed Web of Science ®Google Scholar
• CudkowiczMEShefnerJMSchoenfeldDAA randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisNeurology200361445646412939417
   PubMed Web of Science ®Google Scholar
• MillerRGMooreDH2ndGelinasDFPhase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisNeurology200156784384811294919
   PubMed Web of Science ®Google Scholar
• GurneyMECuttingFBZhaiPBenefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosisAnn Neurol1996391471578967745
   PubMed Web of Science ®Google Scholar
• MillerRGMooreDYoungLAPlacebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study GroupNeurology199647138313888960715
   PubMed Web of Science ®Google Scholar
• KalraSCashmanNRCaramanosZGengeAArnoldDLGabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopyAJNR Am J Neuroradiol200324347648012637300
   PubMed Web of Science ®Google Scholar
• CasanovasARiberaJHukkanenMPrevention by lamotrigine, MK-801 and N omega-nitro-l-arginine methyl ester of motoneuron cell death after neonatal axotomyNeuroscience1996713133259053787
   PubMed Web of Science ®Google Scholar
• EisenAStewartHSchulzerMCameronDAnti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigineCan J Neurol Sci1993202973017906190
   PubMed Web of Science ®Google Scholar
• RybergHAskmarkHPerssonLIA double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parametersActa Neurol Scand20031081812807386
   PubMed Web of Science ®Google Scholar
• SakowskiSASchuylerADFeldmanELInsulin-like growth factor-I for the treatment of amyotrophic lateral sclerosisAmyotroph Lateral Scler200910637318608100
   PubMed Web of Science ®Google Scholar
• LaiECFeliceKJFestoffBWEffect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study GroupNeurology199749162116309409357
   PubMed Web of Science ®Google Scholar
• BorasioGDRobberechtWLeighPNA placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study GroupNeurology1998515835869710040
   PubMed Web of Science ®Google Scholar
• SorensonEJWindbankAJMandrekarJNSubcutaneous IGF-1 is not beneficial in 2-year ALS trialNeurology2008711770177519029516
   PubMed Web of Science ®Google Scholar
• MitchellJDWokkeJHJBorasioGDRecombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron diseaseCochrane Database Syst Rev20074CD00206417943766
   PubMed Web of Science ®Google Scholar
• DodgeJCHaidetAMYangWDelivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activityMol Ther2008161056106418388910
   PubMed Web of Science ®Google Scholar
• Riddoch-ContrerasJYangSYDickJRGoldspinkGOrrellRWGreensmithLMechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) miceExp Neurol200921528128919038252
   PubMed Web of Science ®Google Scholar
• DeChiaraTMVejsadaRPoueymirouWTMice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birthCell1995833133227585948
   PubMed Web of Science ®Google Scholar
• LaaksovirtaHSoinilaSHukkanenVRöyttäMSoilu-HänninenMSerum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onsetEur J Neurol20081535535918353124
   PubMed Web of Science ®Google Scholar
• ALS CNTF Treatment Study GroupA double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study GroupNeurology199646124412498628460
   PubMed Web of Science ®Google Scholar
• MillerRGPetajanJHBryanWWA placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study GroupAnn Neurol1996392562608967757
   PubMed Web of Science ®Google Scholar
• BongioanniPRealiCSogosVCiliary neurotrophic factor (CNTF) for amyotrophic lateralsclerosis or motor neuron diseaseCochrane Database Syst Rev20043CD00430215266526
   PubMedGoogle Scholar
• MalhotraSNijhawanSRosenbaumDMErythropoietin (epoetin) as a protective factor for the brainCurr Atheroscler Rep2004630130615191705
   PubMedGoogle Scholar
• KimSKimHKohSEffectiveness of recombinant human erythropoietin therapy in amyotrophic lateral sclerosis [abstract]Amyotroph Lateral Scler20067Suppl 19
   Google Scholar
• CaldiroliDGhelmaFFerraraGGhezziPMantegazzaRErythropoietin in amyotrophic lateral sclerosis: A pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Neuromuscular Diseases UnitAmyotroph Lateral Scler200952916[Epub ahead of print]19484617
   PubMedGoogle Scholar
• ZhengCSköldMKLiJNennesmoIFadeelBHenterJIVEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic miceBiochem Biophys Res Commun200736398999317923114
   PubMed Web of Science ®Google Scholar
• Tovar-Y-RomoLBZepedaATapiaRVascular endothelial growth factor prevents paralysis and motoneuron death in a rat model of excitotoxic spinal cord neurodegenerationJ Neuropathol Exp Neurol20076691392217917585
   PubMed Web of Science ®Google Scholar
• BogaertEVan DammePPoesenKVEGF protects motor neurons against excitotoxicity by upregulation of GluR2Neurobiol Aging2009128[Epub ahead of print].
   Web of Science ®Google Scholar
• HwangDHLeeHJParkIHIntratechal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS miceGene Ther2009723[Epub ahead of print]
   Web of Science ®Google Scholar
• PitzerCKrügerCPlaasCGranulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosisBrain20081313335334718835867
   PubMed Web of Science ®Google Scholar
• CashmanNTanLYKriegerCMädlerBPilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS)Muscle Nerve20083762062518335482
   PubMed Web of Science ®Google Scholar
• NefussyBArtamonovIDeutschVNaparstekENaglerADroryVERecombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot studyAmyotroph Lateral Scler200951517[Epub ahead of print]19449238
   PubMed Web of Science ®Google Scholar
• AokiMIshigakiINagaiMIntrathecal delivery of hepatocyte growth factor at the onset of paralysis slows disease progression in a rat model of ALS [abstract]Amyotroph Lateral Scler20067Suppl 141
   Google Scholar
• KadoyamaKFunakoshiHOhyaWNakamuraTHepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALSNeurosci Res20075944645617935811
   PubMed Web of Science ®Google Scholar
• SunWFunakoshiHNakamuraTOverexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALSJ Neurosci2002226537654812151533
   PubMed Web of Science ®Google Scholar
• KatoSFunakoshiHNakamuraTExpression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutationActa Neuropathol200310611212012707786
   PubMed Web of Science ®Google Scholar
• OchsGPennRDYorkMA phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord2000120120611464953
   PubMed Web of Science ®Google Scholar
• MitsumotoHIkedaKKlinkoszBCedarbaumJMWongVLindsayRMArrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNFScience1994265110711108066451
   PubMed Web of Science ®Google Scholar
• IkedaKKlinkoszBGreeneTEffects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron diseaseAnn Neurol1995375055117717687
   PubMed Web of Science ®Google Scholar
• BradleyWGA phase I/II study of recombinant brain-derived neurotrophic in patients with ALSAnn Neurol199538971
   Web of Science ®Google Scholar
• BDNF GroupA controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)Neurology1999521427143310227630
   PubMed Web of Science ®Google Scholar
• AcsadiGAnguelovRAYangHIncreased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapyHum Gene Ther2002131047105912067438
   PubMed Web of Science ®Google Scholar
• ManabeYNaganoIGaziMSAdenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosisApoptosis2002732933412101392
   PubMed Web of Science ®Google Scholar
• WangLJLuYYMuramatsuSIkeguchiKNeuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosisJ Neurosci2002226920692812177190
   PubMed Web of Science ®Google Scholar
• SuzukiMMcHughJTorkCDirect muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALSMol Ther2008162002201018797452
   PubMed Web of Science ®Google Scholar
• SuzukiMMcHughJTorkCGDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALSPLoS One200721e68917668067
   PubMed Web of Science ®Google Scholar
• GrundströmELindholmDJohanssonABlennowKAskmarkHGDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosisNeuroreport2000111781178310852244
   PubMed Web of Science ®Google Scholar
• JiangYMYamamotoMKobayashiYGene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosisAnn Neurol20055723625115668976
   PubMed Web of Science ®Google Scholar
• LacomblezLBensimonGDouilletPDopplerVSalachasFMeiningerVXaliproden in amyotrophic lateral sclerosis: early clinical trialsAmyotroph Lateral Scler Other Motor Neuron Disord200459910615204011
   PubMed Web of Science ®Google Scholar
• MeiningerVBensimonGBradleyWREfficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotroph Lateral Scler20045107117
   PubMed Web of Science ®Google Scholar
• MatthewsRTYangLBrowneSBaikMBealMFCoenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effectsProc Natl Acad Sci U S A199895889288979671775
   PubMed Web of Science ®Google Scholar
• FerranteKLShefnerJZhangHTolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALSNeurology2005651834183616344537
   PubMed Web of Science ®Google Scholar
• LevyGKaufmannPBuchsbaumRA two-stage design for a phase II clinical trial of coenzyme Q10 in ALSNeurology20066666066316534103
   PubMed Web of Science ®Google Scholar
• RothsteinJOf mice and men: reconciling preclinical ALS mouse studies and human clinical trialsAnn Neurol20035342342612666108
   PubMed Web of Science ®Google Scholar
• GroeneveldGJVeldinkJHvan der TweelIA randomized sequential trial of creatine in amyotrophic lateral sclerosisAnn Neurol20035343744512666111
   PubMed Web of Science ®Google Scholar
• ShefnerJMCudkowiczMESchoenfeldDA clinical trial of creatine in ALSNeurology2004631656166115534251
   PubMed Web of Science ®Google Scholar
• RosenfeldJKingRMJacksonCECreatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRSAmyotroph Lateral Scler2008926627218608103
   PubMed Web of Science ®Google Scholar
• MazziniLBalzariniCColomboREffects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary resultsJ Neurol Sci200119113914411677005
   PubMed Web of Science ®Google Scholar
• ZhangWNarayananMFriedlanderRMAdditive neuroprotective effects of minocycline with creatine in a mouse model of ALSAnn Neurol20035326727012557297
   PubMed Web of Science ®Google Scholar
• GordonPHCheungYKLevinBA novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSAmyotroph Lateral Scler2008921222218608093
   PubMed Web of Science ®Google Scholar
• DesnuelleCDibMGarrelCFavierAA double-blind, placebo-controlled trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord2001291811465936
   PubMed Web of Science ®Google Scholar
• GrafMEckerDHorowskiRHigh dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind studyJ Neural Transm200511264966015517433
   PubMed Web of Science ®Google Scholar
• VeldinkJHKalmijnSGroeneveldGJIntake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosisJ Neurol Neurosurg Psychiatry20077836737116648143
   PubMed Web of Science ®Google Scholar
• ItoHWateRZhangJTreatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS miceExp Neurol200821344845518718468
   PubMed Web of Science ®Google Scholar
• YoshinoHKimuraAInvestigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)Amyotroph Lateral Scler2006724124517127563
   PubMed Web of Science ®Google Scholar
• PatteeGLPostGRGerberREBennettJPJrReduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatmentAmyotroph Lateral Scler Other Motor Neuron Disord20034909514506939
   PubMed Web of Science ®Google Scholar
• WangHLarriviereKSKellerKER+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALSAmyotroph Lateral Scler20089505818270879
   PubMed Web of Science ®Google Scholar
• GribkoffVKBozikMEKNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosisCNS Neurosci Ther20081421522618801114
   PubMed Web of Science ®Google Scholar
• OrrellRWAEOL-10150 (Aeolus)Curr Opin Investig Drugs200677080
   PubMed Web of Science ®Google Scholar
• PetriSKiaeiMKipianiKAdditive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosisNeurobiol Dis200622404916289867
   PubMed Web of Science ®Google Scholar
• CrowJPCalingasanNYChenJHillJLBealMFManganese porphyrin given at symptom onset markedly extends survival of ALS miceAnn Neurol20055825826516049935
   PubMed Web of Science ®Google Scholar
• AEOLUS Pharmaceuticals. Website. 2006. Available from: http://www.aeoluspharma.com/AEOL10150dev.phpAccessed on October 10, 2009.
   Google Scholar
• BenatarMLost in translation: treatment trials in the SOD1 mouse and in human ALSNeurobiol Dis200726111317300945
   PubMed Web of Science ®Google Scholar
• TokudaEOnoSIshigeKAmmonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosisExp Neurol200821312212818617166
   PubMed Web of Science ®Google Scholar
• AndreassenOADedeogluAKlivenyiPBealMFBushAIN-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosisNeuroreport2000112491249310943709
   PubMed Web of Science ®Google Scholar
• LouwerseESWeverlingGJBossuytPMMeyjesFEde JongJMRandomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosisArch Neurol1995525595647763202
   PubMed Web of Science ®Google Scholar
• BordetTBuissonBMichaudMIdentification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosisJ Pharmacol Exp Ther200732270972017496168
   PubMed Web of Science ®Google Scholar
• BrooksBSanajakMRoelkeKPhase 2B randomized dose-ranging clinical trial of tamoxifen, a selective estrogen receptor modulator (SERM), in amyotrophic lateral scelrosis (ALS): sensitivity analyses of discordance between survival and functional outcomes with long-term follow-upAmyotroph Lateral Scler20056Suppl 1118
   Google Scholar
• KrizJNguyenMDJulienJPMinocycline slows disease progression in a mouse model of amyotrophic lateral sclerosisNeurobiol Dis20021026827812270689
   PubMed Web of Science ®Google Scholar
• ZhuSStavrovskayaIGDrozdaMMinocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in miceNature2002417747811986668
   PubMed Web of Science ®Google Scholar
• Van DenBLTilkinPLemmensGRobberechtWMinocycline delays disease onset and mortality in a transgenic model of ALSNeuroreport2002131067107012060810
   PubMed Web of Science ®Google Scholar
• GordonPHMooreDHGelinasDFPlacebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosisNeurology2004621845184715159491
   PubMed Web of Science ®Google Scholar
• GordonPHMooreDHMillerRGEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialLancet Neurol200761045105317980667
   PubMed Web of Science ®Google Scholar
• SagotYToniNPerreletDAn orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motorneuron diseaseBr J Pharmacol200013172172811030721
   PubMed Web of Science ®Google Scholar
• MillerRBradleyWCudkowiczMPhase II/III randomized trial of TCH346 in patients with ALSNeurology20076977678417709710
   PubMed Web of Science ®Google Scholar
• LiMOnaVOGuéganCFunctional role of caspase-1 and caspase-3 in an ALS transgenic mouse modelScience2000288546433533910764647
   PubMed Web of Science ®Google Scholar
• MeiningerVAsselainBGuilletPPentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trialNeurology200666889216401852
   PubMed Web of Science ®Google Scholar
• AlmerGGueganCTeismannPIncreased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosisAnn Neurol20014917618511220737
   PubMed Web of Science ®Google Scholar
• KlivenyiPKiaeiMGardianGCalingasanNYBealMFAdditive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosisJ Neurochem20048857658214720207
   PubMed Web of Science ®Google Scholar
• DrachmanDBFrankKDykes-HobergMCyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALSAnn Neurol20025277177812447931
   PubMed Web of Science ®Google Scholar
• CudkowiczMEShefnerJMSchoenfeldDATrial of celecoxib in amyotrophic lateral sclerosisAnn Neurol200660223116802291
   PubMed Web of Science ®Google Scholar
• PomplPNHoLBianchiMMcManusTQinWPasinettiGMA therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosisFASEB J20031772572712586733
   PubMed Web of Science ®Google Scholar
• BlairMPeaseMEHammondJEffect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the ratInvest Ophthalmol Vis Sci20054688489015728544
   PubMed Web of Science ®Google Scholar
• BanerjeeRMosleyRLReynoldsADAdaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis micePLoS One200837e274018648532
   PubMed Web of Science ®Google Scholar
• HaenggeliCJulienJPMosleyRLTherapeutic immunization with a glatiramer acetate derivative does not alter survival in G93A and G37R SOD1 mouse models of familial ALSNeurobiol Dis20072614615217276077
   PubMed Web of Science ®Google Scholar
• GordonPHDoorishCMontesJRandomized controlled phase II trial of glatiramer acetate in ALSNeurology200667920
   Web of Science ®Google Scholar
• MeiningerVDroryVELeighPNLudolphARobberechtWSilaniVGlatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trialAmyotroph Lateral Scler20095117[Epub ahead of print]
   Google Scholar
• ShoemakerJLSeelyKAReedRLCrowJPPratherPLThe CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onsetJ Neurochem2007101879817241118
   PubMed Web of Science ®Google Scholar
• KimKMooreDHMakriyannisAAboodMEAM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosisEur J Pharmacol200654210010516781706
   PubMed Web of Science ®Google Scholar
• KiaeiMKipianiKPetriSChenJCalingasanNYBealMFCelastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosisNeurodegener Dis2005224625416909005
   PubMed Web of Science ®Google Scholar
• KiaeiMPetriSKipianiKThalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosisJ Neurosci2006262467247316510725
   PubMed Web of Science ®Google Scholar
• StommelEWCohenJAFadulCEEfficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trialAmyotroph Lateral Scler2009128112[Epub ahead of print]19177249
   PubMedGoogle Scholar
• ListAKurtinSRoeDJEfficacy of lenalidomide in myelodysplastic syndromesN Engl J Med200535254955715703420
   PubMed Web of Science ®Google Scholar
• WestMMhatreMCeballosAThe arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic miceJ Neurochem20049113314315379894
   PubMed Web of Science ®Google Scholar
• Boston-HowesWWilliamsEOBogushAScolereMPasinelliPTrottiDNordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosisExp Neurol200821322923718625223
   PubMed Web of Science ®Google Scholar
• ShibataNKawaguchi-NiidaMYamamotoTToiSHiranoAKobayashiMEffects of the PPARgamma activator pioglitazone on p38 MAP kinase and IkappaBalpha in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosisNeuropathology20082838739818312546
   PubMed Web of Science ®Google Scholar
• SchützBReimannJDumitrescu-OzimekLThe oral antidiaetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic miceJ Neurosci2005257805781216120782
   PubMed Web of Science ®Google Scholar
• KiaeiMKipianiKChenJCalingasanNYBealMFPeroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosisExp Neurol200519133133615649489
   PubMed Web of Science ®Google Scholar
• LorenzlSNarrSAngeleBThe matrix metalloproteinases inhibitor Ro 28-2653 extends survival in transgenic ALS miceExp Neurol200620016617116516196
   PubMed Web of Science ®Google Scholar
• de PaulisTONO-2506Curr Opin Investig Drugs20034863867
   PubMedGoogle Scholar
• ChuangDMChenRWChalecka-FranaszekENeuroprotective effects of lithium in cultured cells and animal models of diseasesBipolar Disord2002412913612071510
   PubMed Web of Science ®Google Scholar
• PasqualiLLongonePIsidoroCRuggieriSPaparelliAFornaiFAutophagy, lithium, and amyotrophic lateral sclerosisMuscle Nerve20094017319419609902
   PubMed Web of Science ®Google Scholar
• FornaiFLongonePCafaroLLithium delays progression of amyotrophic lateral sclerosisProc Natl Acad Sci U S A20081052052220718250315
   PubMed Web of Science ®Google Scholar
• Del SignoreSJAmanteDJKimJStackECCombined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis miceAmyotroph Lateral Scler200910859418618304
   PubMed Web of Science ®Google Scholar
• RyuHSmithKCameloSISodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis miceJ Neurochem2005931087109815934930
   PubMed Web of Science ®Google Scholar
• CudkowiczMEAndresPLMacdonaldSAPhase 2 study of sodium phenylbutyrate in ALSAmyotroph Lateral Scler2009109910618688762
   PubMed Web of Science ®Google Scholar
• GöttlicherMMinucciSZhuPValproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cellsEMBO J2001206969697811742974
   PubMed Web of Science ®Google Scholar
• NilssonMHanssonERonnbackLInteractions between valproate, glutamate, aspartate, and GABA with respect to uptake in astroglial primary culturesNeurochem Res1992173273321355269
   PubMed Web of Science ®Google Scholar
• SugaiFYamamotoYMiyaguchiKBenefit of valproic acid in suppressing disease progression of ALS model miceEur J Neurosci2004203179318315579172
   PubMed Web of Science ®Google Scholar
• FengHLLengYMaCHZhangJRenMChuangDMCombined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse modelNeuroscience200815556757218640245
   PubMed Web of Science ®Google Scholar
• RouauxCPanteleevaIRenéFSodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse modelJ Neurosci2007275535554517522299
   PubMed Web of Science ®Google Scholar
• CrochemoreCVirgiliMBonamassaBLong-term dietary administration of valproic acid does not affect, while retinoic acid decreases, the lifespan of G93A mice, a model for amyotrophic lateral sclerosisMuscle Nerve20093954855219296491
   PubMed Web of Science ®Google Scholar
• PiepersSVeldinkJHDe JongSWRandomized sequential trial of valproic acid in amyotrophic lateral sclerosisAnn Neurol20096622723419743466
   PubMed Web of Science ®Google Scholar
• CorcoranLJMitchisonTJLiuQA novel action of histone deacetylase inhibitors in a protein aggresome disease modelCurr Biol20041448849215043813
   PubMed Web of Science ®Google Scholar
• KalmarBNovoselovSGrayACheethamMEMargulisBGreensmithLLate stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALSJ Neurochem200810733935018673445
   PubMed Web of Science ®Google Scholar
• KieranDKalmarBDickJRRiddoch-ContrerasJBurnstockGGreensmithLTreatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS miceNat Med20041040240515034571
   PubMed Web of Science ®Google Scholar
• CudkowiczMEShefnerJMSimpsonEArimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosisMuscle Nerve20083883784418551622
   PubMed Web of Science ®Google Scholar
• BrooksBRManaging amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of lifeAnn Neurol200965Suppl 1S17S2319191306
   PubMed Web of Science ®Google Scholar
• ScottSKranzJEColeJDesign, power, and interpretation of studies in the standard murine model of ALSAmyotroph Lateral Scler20089141518273714
   PubMed Web of Science ®Google Scholar
• Garbuzova-DavisSSaportaSEvidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALSPLoS One2007211e120518030339
   PubMed Web of Science ®Google Scholar
• HenkelJSBeersDRWenSBowserRAppelSHDecreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALSNeurology200972181614161619414730
   PubMed Web of Science ®Google Scholar
• BeghiEMenniniTBendottiCThe heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failureCurr Med Chem2007143185320018220753
   PubMed Web of Science ®Google Scholar
• Clinical Trials. ALS studies. 2009. Available from: http://www.clinicaltrials.gov/ct2/results?term=als Accessed on October 10, 2009.
   Google Scholar